Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020

Following the approval of Cervarix for the immunization of girls and women in China against high-risk human papillomavirus types 16 and 18, a non-interventional post-authorization safety study was performed. A multi-center prospective cohort study assessed safety following Cervarix vaccination of Ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Qianhui Wu, Mengcen Qian, Sarah Welby, Adrienne Guignard, Dominique Rosillon, Kusuma Gopala, Yuan Xu, Keruo Liu, Yunkun He, Ning Jiang, Qin Tan, Jiamin Xie, Taoying Zhu, Qizhang Wang, Yingzi Pan, Ruikun Zeng, Jie Yang, Xiaoqian Zhao, Man Zhou, Adoración Navarro-Torné, Hongjie Yu, Dorota Borys
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
China
HPV-16/18 AS04-adjuvanted vaccine
human papillomavirus
post-marketing
pregnancy
safety
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2283912
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items